Swiss National Bank
ATRA icon

Swiss National Bank’s Atara Biotherapeutics ATRA Stock Holding History

Swiss National Bank’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-6,960
Closed -$505K – 2608
2023
Q1 		$505K Sell
6,960
-788
-10% -$76.4K ﹤0.01% 2516
2022
Q4 		$635K Buy
7,748
+292
+4% +$30.4K ﹤0.01% 2519
2022
Q3 		$705K Hold
7,456
– – ﹤0.01% 2466
2022
Q2 		$1.45M Buy
7,456
+348
+5% +$56.8K ﹤0.01% 2139
2022
Q1 		$1.65M Buy
7,108
+792
+13% +$252K ﹤0.01% 2140
2021
Q4 		$2.49M Hold
6,316
– – ﹤0.01% 1911
2021
Q3 		$2.83M Buy
6,316
+48
+0.8% +$17.2K ﹤0.01% 1827
2021
Q2 		$2.44M Sell
6,268
-476
-7% -$170K ﹤0.01% 1975
2021
Q1 		$2.42M Buy
6,744
+360
+6% +$159K ﹤0.01% 1897
2020
Q4 		$3.13M Buy
6,384
+220
+4% +$102K ﹤0.01% 1652
2020
Q3 		$2M Buy
6,164
+92
+2% +$31.3K ﹤0.01% 1719
2020
Q2 		$2.21M Buy
6,072
+2,292
+61% +$579K ﹤0.01% 1658
2020
Q1 		$804K Buy
3,780
+80
+2% +$25.4K ﹤0.01% 1954
2019
Q4 		$1.52M Buy
3,700
+144
+4% +$49.6K ﹤0.01% 1884
2019
Q3 		$1.25M Buy
3,556
+464
+15% +$173K ﹤0.01% 1938
2019
Q2 		$1.55M Buy
3,092
+760
+33% +$536K ﹤0.01% 1852
2019
Q1 		$2.32M Buy
2,332
+88
+4% +$81.8K ﹤0.01% 1578
2018
Q4 		$1.95M Buy
2,244
+140
+7% +$130K ﹤0.01% 1592
2018
Q3 		$2.17M Hold
2,104
– – ﹤0.01% 1663
2018
Q2 		$1.93M Hold
2,104
– – ﹤0.01% 1735
2018
Q1 		$2.05M Buy
2,104
+960
+84% +$875K ﹤0.01% 1622
2017
Q4 		$518K Hold
1,144
– – ﹤0.01% 2400
2017
Q3 		$473K Hold
1,144
– – ﹤0.01% 2395
2017
Q2 		$400K Hold
1,144
– – ﹤0.01% 2466
2017
Q1 		$588K Buy
1,144
+100
+10% +$41.4K ﹤0.01% 2313
2016
Q4 		$371K Hold
1,044
– – ﹤0.01% 2482
2016
Q3 		$558K Hold
1,044
– – ﹤0.01% 2309
2016
Q2 		$588K Hold
1,044
– – ﹤0.01% 2263
2016
Q1 		$479K Buy
1,044
+208
+25% +$93.6K ﹤0.01% 2325
2015
Q4 		$552K Hold
836
– – ﹤0.01% 2202
2015
Q3 		$657K Buy
836
+276
+49% +$337K ﹤0.01% 2029
2015
Q2 		$739K Buy
+560
New +$642K ﹤0.01% 1993

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Swiss National Bank's ATRA Position: Q2 2023 in Review

Swiss National Bank sold out of Atara Biotherapeutics (ATRA) in Q2 2023, closing a stake of 6,960 shares — an estimated $505K sold.

Swiss National Bank first reported a position in ATRA in Q2 2015 and held it in 32 quarters. The position peaked at $3.13M in Q4 2020. 118 funds tracked by Wall St. Rank hold ATRA as of Q2 2023.

  • Swiss National Bank reported no remaining Atara Biotherapeutics position as of Q2 2023 after selling out during the quarter.
  • Swiss National Bank sold 6,960 Atara Biotherapeutics shares in Q2 2023, an estimated $505K.
  • Swiss National Bank first reported a position in Atara Biotherapeutics in Q2 2015 and held it in 32 quarters.
  • Swiss National Bank's Atara Biotherapeutics position peaked at $3.13M in Q4 2020.
  • 118 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2023.

Based on Swiss National Bank's 13F filing for Q2 2023, filed 9 Aug 2023.